August 10, 2026
Energenesis and Taiwan Tanabe to develop ENERGI-F703DFU for DFUs
Energenesis Biomedical has signed a joint development agreement with Taiwan Tanabe Seiyaku for its investigational topical drug ENERGI-F703DFU to treat diabetic foot ulcers (DFUs).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.







